Clinical trials: Ticagrelor
Acute Coronary Syndrome
Impact of Evolocumab on the Antiplatelet Effects of Ticagrelor and Aspirin in Patients With Acute Coronary Syndrome
The aim of the present study is to investigate the effects of evolocumab in addition to statin therapy on platelet reactivity in patients with acute coronary syndrome (ACS) while on Ticagrelor and Aspirin treatment.
- Trial name
- EvoACS (NCT05418166)
- Testing
- Evolocumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Inhibition on Platelet Aggregation
Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets
Study to see if platelet transfusion stop or lessen the effect of the drug on platelets
- Trial name
- NCT01744288
- Testing
- Ticagrelor, Clopidogrel, ASA
- Where
- United States
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Intracranial Arteriosclerosis, Stroke
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular…
- Trial name
- CAPTIVA (NCT05047172)
- Testing
- Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin
- Where
- 114 sites in United States
- Volunteers
- 1,683 people
- Sponsor
- University of Florida
ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
Randomized clinical study evaluating superiority in platelet inhibition after administration of Ticagrelor 180 mg loading dose as an orodispersible formulation versus traditional coated tablets in patients admitted for ST…
- Trial name
- TASTER (NCT03822377)
- Testing
- Ticagrelor orodispersible tablets, Ticagrelor standard tablets
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- Azienda Ospedaliero Universitaria di Sassari
Acute Ischaemic Stroke, Transient Ischaemic Attack
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events
- Trial name
- THALES (NCT03354429)
- Testing
- Ticagrelor
- Where
- 387 sites in Argentina, Australia and 26 more
- Volunteers
- 11,016 people
- Sponsor
- AstraZeneca
Chronic Coronary Syndrome
Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease
This is a prospective, multicenter, randomized, open-label trial with blinded endpoint adjudication (PROBE design), comparing one-month dual antiplatelet therapy (DAPT) with low-dose ticagrelor (60 mg BID) followed by ticagrelor…
- Trial name
- STELAR (NCT07080684)
- Testing
- Ticagrelor 60 mg, clopidogrel 75 mg
- Volunteers
- 1,000 people
- Sponsor
- University of Messina
Acute Coronary Syndromes
A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta
To identify the following items through the post marketing surveillance under routine clinical practice after marketing authorization of Brilinta Tablet: the occurrence of unrevealed Serious Adverse Events (SAEs), current status…
- Trial name
- NCT01611272
- Where
- 23 sites in South Korea
- Volunteers
- 3,402 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)
To compare the clinical outcomes of dual antiplatelet therapy with aspirin and ticagrelor vs. ticagrelor monotherapy at 3 months after PCI in patients with acute coronary syndrome.
- Trial name
- NCT02494895
- Testing
- Ticagrelor monotherapy, Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)
- Where
- South Korea
- Volunteers
- 3,056 people
- Sponsor
- Yonsei University
Acute Coronary Syndrome
Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery
The aim of CyTation is to demonstrate intra-operative removal of ticagrelor by CytoSorb® hemadsorption in patients on ticagrelor undergoing emergent cardiothoracic surgery requiring CPB, using platelet reactivity to adenosine…
- Trial name
- CyTation (NCT04625764)
- Testing
- Blood sampling and analysis
- Where
- 4 sites in Germany, Luxembourg
- Volunteers
- 6 people
- Sponsor
- CytoSorbents Europe GmbH
Diabetes Mellitus, Coronary Artery Disease
Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes
Patients with diabetes mellitus (DM) have an increased risk of adverse atherothrombotic events. This may be in part attributed to the fact that these patients have reduced response to oral antiplatelet medications, in particular…
- Trial name
- NCT01852214
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Myocardial Infarction, ST Segment Elevation Myocardial Infarction (STEMI)
A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study
This is a prospective randomized study, which investigates the coronary microvascular function as assessed by coronary angiography after administration of ticagrelor compared with clopidogrel in patients with myocardial…
- Trial name
- MIRTOS (NCT02429271)
- Testing
- Ticagrelor, Clopidogrel, Percutaneous Coronary Intervention (PCI)
- Where
- Greece
- Volunteers
- 336 people
- Sponsor
- Hellenic Cardiovascular Research Society
Coronary Artery Disease
1-month vs 12-month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials
Prospective, multicenter, randomized, double-blind, placebo-controlled trials.
- Trial name
- NCT03971500
- Testing
- AntiPlatelet therapy, Percutaneous coronary intervention
- Where
- China
- Volunteers
- 3,710 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Platelet Reactivity
Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis
Clopidogrel administration is commonly prescribed in patients undergoing percutaneous coronary intervention, in patients with previous stroke and in patients under chronic hemodialysis via fistulae.
- Trial name
- NCT01511471
- Testing
- Ticagrelor
- Where
- 2 sites in Greece
- Volunteers
- 20 people
- Sponsor
- University of Patras
Acute Coronary Syndrome
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes
The McGill University Health Center (MUHC) Division of Cardiology, with funding from the Canadian Institute of Health Research, is performing this randomized controlled trial to determine which dual antiplatelet therapy (DAPT)…
- Trial name
- TC4 (NCT04057300)
- Testing
- Ticagrelor 90mg, Clopidogrel 75mg, acetylsalicylic acid (ASA) 81mg
- Where
- Canada
- Volunteers
- 1,038 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Myocardial Infarction (MI)
Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI).
- Trial name
- STREAMLINE (NCT07507500)
- Testing
- Prasugrel, Ticagrelor
- Where
- 5 sites in Ireland, Latvia and 3 more
- Volunteers
- 8,100 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Unstable Angina
Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris
The purpose of this study is to evaluate differences in the pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite in patients who received ticagrelor followed with methoxyflurane versus ticagrelor followed…
- Trial name
- METHANE (NCT04442919)
- Testing
- Ticagrelor followed with Methoxyflurane, Ticagrelor followed with Morphine, Ticagrelor alone
- Where
- Poland
- Volunteers
- 72 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Unruptured Intracranial Aneurysm, Infarction Cerebral
Chronic Remote Ischemic Conditioning in Small Infarctions Associated with Stent-assisted Coiling of Unruptured Intracranial Aneurysms
1. Disease Description Stent-assisted coiling has become an effective treatment modality for intracranial aneurysms. With continuous advancements in periprocedural antiplatelet regimens, the incidence of symptomatic…
- Trial name
- CRISIS (NCT06826144)
- Testing
- remote ischemic conditioning
- Volunteers
- 84 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Type 2 Diabetes Mellitus；, Stable Coronary Disease
A Pilot Study To Examine The Effects Of Ticagrelor To Protect Against Type 2 Diabetes-Induced Vascular Damage
The purpose of this study is to compare clopidogrel with ticagrelor which one has stronger anti-inflammation effect to protect against type 2 diabetes-induced vascular damage.
- Trial name
- NCT02214654
- Where
- 2 sites in China
- Volunteers
- 144 people
- Sponsor
- Tianjin Medical University
Treatment of Acute Coronary Syndrome (ACS).
REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.
REWINDER is a multinational, multicentre, non-interventional, retrospective study of patients treated with an oral antiplatelet (ticagrelor, prasugrel or clopidogrel) while in hospital after an acute coronary syndrome (ACS)…
- Trial name
- REWINDER (NCT02190123)
- Testing
- ACS patients treated with OAP
- Where
- 15 sites in Belgium
- Volunteers
- 430 people
- Sponsor
- AstraZeneca
Thrombosis, Stent Thrombosis
Evaluating Pharmacogenomic Variants for Cardiology Therapeutics
Cipherome's Lighthouse is a clinical decision support tool that incorporates a patient's pharmacogenetic information to determine therapeutic strategy, including determining appropriate dosage or assessing the likelihood of…
- Conditions
- Thrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction
- Trial name
- CARES2 (NCT04702113)
- Testing
- Cipherome Lighthouse Pilot
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Cipherome, Inc.